The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2010Modulation of the Rho Kinase pathway for improvement of regeneration in PD
Objective/Rationale:
A characteristic feature of Parkinson’s disease is the loss of axons, the long processes of neuronal cells. This loss of axons seems to occur early in the course of the disease... -
Rapid Response Innovation Awards, 2010SNCA Haplotyping in Parkinson's Disease and Multiple System Atrophy
Objective/Rationale:
A succinct, lay-oriented statement of the scientific rationale for this project. We have recently shown that genetic variants at the SNCA gene locus, coding for the alpha-synuclein... -
Rapid Response Innovation Awards, 2010Resting State fMRI as a Biomarker for Parkinson's Disease
Objective/Rationale:
There is an increasingly interest in finding biomarkers that can objectively evaluate the disease progression and the effects of neuroprotective treatment on the course of... -
Rapid Response Innovation Awards, 2010Identification and Validation of the Modifiers of LRRK2-induced Toxicity
Objective/Rationale:
Mutations in LRRK2 gene have been identified as an unambiguous cause of rare autosomal dominant forms of PD. A number of useful models have been developed to study the... -
Rapid Response Innovation Awards, 2010Protecting Innervation: Nmnat1 Gene Therapy for Parkinson's Disease
Objective/Rationale:
Axonal degeneration is a major pathological hallmark of Parkinson’s disease (PD). Evidence gathered in PD patients indicates that pathology in axons occurs prior to and... -
Rapid Response Innovation Awards, 2010CSF Lysosomal Hydrolases' Activity as Possible Marker of Parkinson's Disease
Objective/Rationale:
Recent studies have linked lysosomal dysfunction to the accumulation of alpha-synuclein oligomers and alpha-synuclein-mediated cell death. Clinical, neuropathological and genetic...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.